AI and community health workers team up to help diabetes patients after hospital stays

NCT ID NCT07599852

Not yet recruiting Disease control Sponsor: University of Alabama at Birmingham Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a 3-month support program, led by a nurse and a community health worker and guided by an AI tool called MEDBRIDGE, can help people with type 2 diabetes manage their medications after leaving the hospital. The program aims to reduce confusion about medication changes and prevent emergency visits. Forty-five adults from two Alabama hospitals will take part to see if the program is practical and acceptable.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nurse case manager and community health worker support program
What this could lead to: If it works, this could point toward a practical way to help people with diabetes avoid medication mix-ups and hospital readmissions after discharge.
What could go wrong: This is a very small, early feasibility study with only 45 participants, so results may not apply broadly. The program may not improve blood sugar or reduce emergency visits as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARE TRANSITION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Medication Adherence type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARE TRANSITION MEDICATION ADHERENCE MEDICATION DISCREPANCY TYPE 2 DIABETES

Contacts and locations

Locations

Cooper Green Mercy Health Services

Birmingham, Alabama, 35233, United States
University of Alabama at Birmingham

Birmingham, Alabama, 35223, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.